arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

download Export Data

Kyverna Therapeutics, Inc.

KYTX

$7.96 ▲ +0.20 (+2.58%) at close

4 Visible periods

19 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Poor

Bearish

auto_awesome

Analytical Summary

Kyverna Therapeutics, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $352.3M

Dividend Yield —

Revenue Growth —

Op. Margin —

ROIC -57.8% ↘

FCF / Share $-3.47 ↘

Trailing P/E —

Price / Book 2.1x

FCF Yield —

Debt / Equity —

info Valuation on last close. End-of-day price, Aug 7, 2026.

4-Year Financial Trajectory

Annual

Metric Value Trend Year over Year Percentile

Net Income Profit after all expenses

$-161.31M

↓ -26.5% —

FCF / Share Free cash flow per share

$-3.47

↓ -14.3% —

trending_up

Bullish Indicators

No bullish signals detected.

warning

Bearish Risks

Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns

Financial Health ↓

Cash Quality ↑

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗
EPS Growth YoY (%)	-9.3% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	96.3% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	—	—
Net Income Growth YoY (%)	-26.5% Weak Weak Year-over-year change in net income	-111.2% Weak Weak Year-over-year change in net income	—	—
FCF Growth YoY (%)	-14.3% Weak Weak Year-over-year change in free cash flow	96.1% Excellent Excellent Year-over-year change in free cash flow	—	—

💰 Are margins durable? 1 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗
FCF / Net Income (x)	0.95x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.91x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	0.88x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	—

🎯 Is capital allocation efficient? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗
Return on Invested Capital (%)	-57.8% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-42.3% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	37.5% Excellent Excellent Return earned on debt + equity capital invested Optimal: > 10%	—
Return on Capital (%) (%)	-57.8% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-46.8% Weak Weak Operating profit relative to total assets Optimal: > 10%	-83.0% Weak Weak Operating profit relative to total assets Optimal: > 10%	—
Return on Common Equity (%) (%)	-69.4% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-563%)	-47.8% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-419%)	45.9% Excellent Excellent Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+206%)	—

⚖️ Is the balance sheet risky? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗
Interest Coverage (x)	-409.22x Weak ↑ Weak Improving Operating income divided by interest expense Optimal: > 5x	-1004.25x Weak Weak Operating income divided by interest expense Optimal: > 5x	-333.72x Weak Weak Operating income divided by interest expense Optimal: > 5x	—
Net Debt (USD)	$-124.09M	$-96.62M	$-34.65M	—

📊 What does each share earn? 5 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗
Basic EPS, GAAP (USD)	$-3.64	$-3.33	$-89.61	—
Free Cash Flow per Share (USD)	$-3.47	$-3.04	$-78.73	—
Book Value per Share (USD)	$3.85	$6.17	$-105.11	—
Tangible Book Value per Share (USD)	$3.85	$6.17	$-105.11	—
Basic Weighted Avg Shares (shares)	44.26M	38.33M	673,622	—

🏦 How resilient is the balance sheet? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗
Working Capital (USD)	$246.47M	$256.85M	$40.80M	—
Total Equity (USD)	$232.28M	$266.59M	$-131.40M	$-74.00M

📋 What is driving earnings? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗
Depreciation Expense (USD)	$1.80M	$2.13M	$1.71M	—
Net Income, GAAP (USD)	$-161.31M	$-127.48M	$-60.37M	—
Operating Cash Flow (USD)	$-153.71M	$-114.25M	$-52.41M	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 4 years · 14 quarters

Kyverna Therapeutics, Inc.

Analytical Summary

4-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Signals

Percentile Rankings

Peer Comparison

Compare KYTX with peers